Biotech startup Nucleome Therapeutics has raised £37.5m in an oversubscribed Series A round to discover new medicines by decoding the human genome.
The investment will be spent on Nucleome’s autoimmune disease programmes alongside further research and development.
Dr Danuta Jeziorska, CEO and co-founder of Nucleome Therapeutics, said: “We have already made significant progress by mapping genes to genetics in a number of human immune cell types and discovering the first wave of potential first-in-class autoimmune disease targets”
Oxford-spinout Nucleome Therapeutics has found a way to look at the dark area of the human genome, an area where 90% of disease-associated genetic changes occur and holds promise for discovering new drugs.
The startup uses machine learning to predict disease-linked genetic variants that “create and destroy functional elements in the dark genome”. Led by M Ventures, the Nucleome Therapeutics Series A also saw capital invested by Johnson and Johnson, Pfizer Ventures, British Patient Capital and Oxford Science Enterprises.
“Nucleome’s differentiated platform technology has the potential to fundamentally shift the way we discover and develop precision medicines,” said Dr Bauke Anninga, principal, M Ventures.
“We are excited to lead this financing, and alongside our co-investors, partner with Nucleome’s exceptional team to advance their target and drug discovery programmes to bring transformative treatments to patients.”
